Effects of bezafibrate in patients with diabetes and abnormalities of lipid metabolism

Therapeutic Research

Volumn 32, Issue 10, 2011, Pages 1317-1324

  Fujiwara, Masazumi ^a  

^a Saiseikai Saijo Hospital   (Japan)

Author keywords

Adipotoxicity; Bezafibrate; HbA1c; Insulin resistance; Lipid metabolism abnormalities

Indexed keywords

ANTIDIABETIC AGENT; BEZAFIBRATE; BUFORMIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; MITIGLINIDE; PIOGLITAZONE; VOGLIBOSE;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; BODY MASS; DIABETES MELLITUS; DISORDERS OF LIPID AND LIPOPROTEIN METABOLISM; DRUG EFFECT; DRUG WITHDRAWAL; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; RETCHING; RHABDOMYOLYSIS; SIDE EFFECT;

EID: 82155186208     PISSN: 02898020     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. BMJ 1998;317:703-13.
2. Gaede P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 2008;358:580-91. (Pubitemid 351214285)
3. Tenenbaum H, Behar S, Boyko V, Adler Y, Fisman EZ, Tanne D, et al. Long-term effect of bezafibrate on pancreatic beta-cell function and insulin resistance in patients with diabetes. Atherosclerosis 2007;194:265-71. (Pubitemid 47495923)
4. Taniguchi A, Fukushima M, Sakai M, Tokuyama K, Nagata I, Fukunaga A, et al. Effects of bezafibrate on insulin sensitivity and insulin secretion in non-obese Japanese type 2 diabetic patients. Metabolism 2001;50:477-80. (Pubitemid 32321960)
5. Willson TM, Brown PJ, Sternbach DD, Henke BR The PPARs: From orphan receptors to drug discovery. J Med Chem 2000;43:527-50. (Pubitemid 30127149)
6. Ferré, P. The biology of peroxisome proliferator-activated receptors: relationship with lipid metabolism and insulin sensitivity. Diabetes 2004;53:S43-50. (Pubitemid 38168692)
7. Shimabukuro M, Higa N, Asahi T, Yamakawa K, Oshiro Y, Higa M, et al. Impaired glucose tolerance, but not impaired fasting glucose, underlies left ventricular diastolic dysfunction. Diabetes care 2011;34:686-90.
8. Okazaki M, Usui S, Ishigami M, Sakai N, Nakamura T, Matsuzawa Y, et al. Identification of unique lipoprotein subclasses for visceral obesity by component analysis of cholesterol profile in high-performance liquid chromatography. ArteriosclerThromb Vasc Biol 2005;25:578-84. (Pubitemid 40315681)
9. Duez H, Lamarche B, Uffelman KD, Valero R, Cohn JS, Lewis GF. Hyperinsulinemia is associated with increased production rate of internal apolipoprotein B-46-containing lipoproteins in humans. Arterioscler Thromb Vasc Biol 2006;26:1357-63. (Pubitemid 44305382)
10. Chapman MJ. Fibrates in 2003: therapeutic action in atherogenic dyslipidaemia and future perspectives. Atherosclerosis 2003;171:1-13. (Pubitemid 37474095)
11. Tenenbaum A, Fisman EZ, Boyko V, Benderly M, Tanne D, Haim M, et al. Attenuation of progression of insulin resistance in patients with coronary artery disease by bezafibrate. Arch Intern Med 2006;166:737-41.
12. Wu J, Song Y, Li H, Chen J. Rhabdomyolysis associated with fibrate therapy: review of 76 published cases and a new case report. Eur J Clin Pharmacol 2009;65:1169-74.
13. Kissei Pharmaceutical Co., Ltd. Bezatol® SR Tablets (package insert). Revised in June 2009 (Ver. 12).